Læknablaðið - 15.07.2012, Blaðsíða 14

RANNSÓKN
Heimildir
1. Newcomer JW. Metabolic syndrome and mental illness.
Am J Manag Care 2007; 13(7 Suppl): S170-7.
2. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM,
Sullivan L, et al. Prevalence of the metabolic syndrome
in patients with schizophrenia: baseline results from the
Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) schizophrenia trial and comparison with national
estimates from NHANES III. Schizophr Res 2005; 80:
19-32.
3. Hágg S, Lindblom Y, Mjömdal T, Adolfsson R. High preva-
lence of the metabolic syndrome among a Swedish cohort
of patients with schizophrenia. Int Clin Psychopharmacol
2006;21:93-8.
4. Birkenaes AB, Sogaard AJ, Engh JA, Jonsdottir H, Ringen
PA, Vaskinn A, et al. Sociodemographic characteristics and
cardiovascular risk factors in patients with severe mental
disorders compared with the general population. J Clin
Psychiatry 2006; 67: 425-33.
5. Medical Illness and Schizophrenia. Ed. Meyer J, Nasrallah
H. Arlington, American Psychiatric Publishing, 2003.
6. McEvoy JP, Brown S. Smoking in first-episode patients
with schizophrenia. Am J Psychiatry 1999; 156:1120-1.
7. Pramyothin P, Khaodhiar L. Metabolic syndrome with the
atypical antipsychotics. Curr Opin Endocrinol Diabetes
Obes 2010; 17:460 -6.
8 Wirshing DA, Wirshing WC, Kysar L, Berisford MA,
Goldstein D, Pashdag J, et al. Novel antipsychotics:
comparison of weight gain liabilities. J Clin Psychiatry
1999; 60:358-63.
9. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy
lifestyle of people with schizophrenia. Psychol Med 1999;
29: 697-701.
10. Davidson S, Judd F, Jolley D, Hocking B, Thompson S,
Hyland B. Cardiovascular risk factors for people with
mental illness. Aust NZ J Psychiatr 2001; 35:196-202.
11. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM,
Stroup TS, et al. Low rates of treatment for hypertension,
dyslipidemia and diabetes in schizophrenia: Data from the
CATIE schizophrenia trial sample at baseline. Schizophr
Res 2006; 86:15-22.
12. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L,
Lucksted A, et al. Prevalence and correlates of diabetes in
national schizophrenia samples. Schizophr Bull 2000; 26:
903-12.
13. Henderson DC, Cagliero E, Gray C, Nasrallah RA,
Hayden DL, Shoenfeld DA, et al. Clozapine, diabetes
mellitus, weight gain, and lipid abnormalities: a five-year
naturalistic study. Am J Psychiatry 2000; 157:975-81.
14. Mclntyre RS, McCann SM, Kennedy SH. Antipsychotic
metabolic effects: weight gain, diabetes mellitus, and lipid
abnormalities. Can J Psychol 2001; 46: 273-81.
15. Handbók Hjartavemdar 2008 - hjarta.is
16. Meyer JM, Stahl SM. The metabolic syndrome and schi-
zophrenia. Acta Psychiatr Scand 2009; 119:4-14. Review.
ENGLISH SUMMARY
A study of risk factors for cardiovascular disease among schizophrenic
patients using the rehabilitation mental health services at Kleppur
Sveinsson O12, Thorleifsson K', Aspelund Th34, Kolbeinsson H'
Background: Studies have shown that schizophrenic patients die
on average 15-20 years earlier than the normal population, and that
increased prevalance of cardiovascular risk factors plays a crucial
role Schizophrenic patients are underdiagnosed and undertreated
when it comes to diabetes, hypertension and dyslipidemia. The aim of
this study was to investigate the prevalence of metabolic syndrome,
obesity, hypertension, diabetes and dyslipidemia among schizophrenic
patients in lceland.
Methods: An observational study of 106 schizophrenic patients in
lceland during the period 2007-2009. The results were compared to age
adjusted population based data.
Results: 106 patients participated, 86 men and 20 women. In all 57%
were diagnosed with metabolic syndrome (p<0.0001) in comparison to
14.1% in the general population. In all 73% were smokers (21% in the
general population) p<0.0001 and 23.6% had hypertension of which
only 20% were treated with anti-hypertensive medication. The average
systolic blodpressure was 134.8 mmHg <0.001. In all 15.1% had a
fasting glucose over 7 mmol/l but only 38% were previously diagnosed
with diabetes. The average BMI was 29.7 kg/m2 p=0.0007, 45.3% were
obese (BMI >30 kg/m2). Only 32.1% had normal BMI, and 82.1% had
waist circumference over the normal limits.
Conclusion: The physical condition of lcelandic schizophrenic patients
is poor and their risk for cardiovascular diseases is high. It is necessary
to follow their weight, blood pressure, blood glucose and lipids more
closely It is imperative to educate and enable the schizophrenic patient
to live a healthier life
Correspondence: Ólafur Sveinsson, olafur.sveinsson@karolinska.se
Key words: Metabolic syndrome, hypertension, diabetes, prevalence, schizophrenia, dyslipidemia.
’Rehabilitation Mental Health Services, The National University Hospital of lceland, 2Department of Neurology, Karolinska University Hospital, Stockholm,
Sweden, 3lcelandic Heart Association, ‘University of lceland
402 LÆKNAblaðið 2012/98